Tobramycin Level
No Results
No Results
processing….
Tobramycin is an aminoglycoside antibiotic that is used for treatment of infections of susceptible strains of aerobic gram-negative bacteria that are resistant to less-toxic antibiotics. In particular, it has been more commonly used for definitive or empirical treatment of Acinetobacter, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Providencia stuartii, and sometimes Serratia. [1, 2]
The reference ranges for serum tobramycin levels are listed below. [3, 4, 1]
The reference ranges for tobramycin administered every 8 hours (sometimes up to 12 hours), also called “traditional”, “conventional”, or “multiple-daily” dosing are as follows:
Tobramycin, peak
Therapeutic: 5-10 mcg/mL
Tobramycin, trough
Therapeutic: < 2 mcg/mL
No standard reference range exists for a tobramycin level when administered as a single-daily dose. Instead, serum concentrations are taken hours after infusion (please see below) and are either plotted graphically onto a nomogram or encoded onto a computer to generate a 24-hour area under the curve (AUC). A final, but less validated, method involves checking a level at the end of the anticipated dosing interval to ensure that it is less than 1 mcg/mL. [5, 6]
For the nomogram method: One serum concentration 6-14 hours after the start of the infusion. Use the nomogram below and adjust as directed. [1, 7, 8]
See the list below:
For the 24-hour area under the curve (AUC) method, 2 serum concentrations are taken: The first is 1 hour after infusion and the second is 6 hours after infusion. A computer program then generates a 24-hour AUC and recommends the appropriate dose or interval change (please see below for links to free programs online). [1, 7, 8]
Another commonly used method is to check for a trough level before the second dose would have been given, with the goal of keeping the trough level < 1 mcg/mL. [2]
For tobramycin administered in multiple daily doses (usually every 8-12 hours), peak and trough levels guide tobramycin dosing. Peak levels are used to adjust the tobramycin dose per administration and should be within the reference range to be considered therapeutic. Subsequent tobramycin doses are either increased or decreased to attain levels within this range. [1, 9]
Trough levels, on the other hand, are used to modify the dosing intervals. The goal is to keep the trough levels below the designated reference value to prevent accumulation and toxicity. [1, 2]
Tobramycin administered using an extended interval is monitored and adjusted using a 24-hour AUC, a nomogram, or based on an end of interval level. A 24-hour AUC, as aforementioned, is computer-generated and derived from 2 serum concentrations (at 1 and 6 hours after finish or start of IV infusion) and provides computer-generated recommendations on dose adjustments. [1, 8, 2, 10] Examples of computerized AUC methods that are available online for free include Aladdin and TCIWorks.
Another method using a nomogram plots a single serum concentration taken 6-14 hours after the end of the IV infusion onto a graph (see below). This is less accurate than the computer-based method but requires only one drug level and is more readily available. It is well-studied only in adults and has been demonstrated to work well in patients with normal or mildly impaired renal function (creatinine clearance between 60-90 mL/min/1.73 m2); caution should be taken in interpreting results of patients with more severe renal impairment. Dosing interval changes, namely whether to maintain the usual 24-hour administration interval or to increase it to every 36-48 hours, are based on where the serum concentration falls on the nomogram. If a level falls on the border between 2 dosing intervals, the longer is chosen because efficacy will likely be preserved and the chances of level accumulation and toxicity will be minimized. [1, 8, 2, 11, 10]
Another simple, commonly used method is to check the trough level at the end of the dosing interval, before the second dose. One obvious drawback is that you cannot confirm that the dose is appropriate until the second dose is due. When the level is less than 1 mcg/mL, the dose and interval can safely be continued. If the dose is elevated, then longer intervals will be needed and, if significantly elevated, one may need to use one of the above methods to determine an alternate regimen. This method is less reliable compared with the other methods, and caution is required in interpreting its results. A study on patients with cystic fibrosis showed that the extended-interval dosing resulted in higher drug levels in excess of those associated with the multiple-daily dosing, despite having a trough level at goal. [5]
See the list below:
Specimen: Blood
Container: Red-top tube
Collection method: Routine venipuncture (at least 5 mL); finger-prick (< 0.5 mL) [12]
Collection times are as follows:
Conventional (multiple-daily) dosing: Ideally, peak and trough levels should be collected when the antibiotic is presumed to be in steady-state, which is usually around the third dose. Collect blood for peak level 30-60 minutes after completion of an intravenous dose or 60-90 minutes after an intramuscular dose. Collect blood for trough level within 30 minutes of the next dose. [4, 7]
Extended interval (single-daily) dosing: Serum random levels can be measured after the first dose of the antibiotic. As elucidated above, collect a 1-hour and 6-hour post-infusion serum for the computer-based method, and a single serum sample between 6-14 hours from the start of infusion for the nomogram method. [4, 7, 13] Serum “trough” or “end-interval” levels are collected within 30 minutes of the subsequent dose. Do not use the tobramycin trough reference ranges provided above, as these are standardized for conventional dosing. (The goal with this method is < 1 mcg/mL.)
For both dosing methods, serum levels are usually repeated every 3-7 days or more frequently when clinically warranted.
Tobramycin is an aminoglycoside antibiotic that is used for treatment of infections of susceptible strains of aerobic gram-negative bacteria that are resistant to less-toxic antibiotics. In particular, it has been more commonly used for definitive or empirical treatment of Acinetobacter, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Providencia stuartii, and sometimes Serratia. [1, 2]
Tobramycin, which is administered parenterally, either intravascularly or intramuscularly, reaches peak serum concentrations in 30-90 minutes. Conventional (multiple-daily) doses of this aminoglycoside do not usually lead to accumulation except in patients with renal impairment and in neonates. Dosage for such patients must, therefore, be adjusted accordingly. [1, 2]
Extended interval (single daily) dosing has the theoretical advantage of minimizing the risk of toxicity while still optimizing bacterial killing with delivery of fewer but higher doses of the antibiotic. At the end of each dosing interval, tobramycin level is expected to reach very low serum concentrations (< 1 mcg/mL) but still continues to have antibacterial activity (also called postantibiotic effect), making the single-daily dosing a feasible alternative regimen. Please see the image below that shows differences in serum concentration over time between the 2 dosing regimens. [14]
Like other aminoglycosides, tobramycin has intrinsic toxicity. It can cause reversible nonoliguric nephrotoxicity, irreversible vestibulocochlear toxicity, and neuromuscular blockade, among others. [4, 2]
Serum tobramycin levels are recommended in the following settings: [4, 8, 15, 16]
Premature infants and neonates up to 3 months
Patients with impaired renal function, fluctuating renal function, on dialysis, or those who are critically ill
Co-existence of disease states known to increase toxicity, such as, but not limited to dehydration, volume depletion, hypotension, concurrent liver disease, metabolic acidosis, hypokalemia, and hypomagnesemia
Dose change or if planning on prolonged therapy (>3 days for single-daily dosing, or >7 days for multiple-daily dosing)
Signs or symptoms of toxicity
If tobramycin is coadministered with drugs known to potentiate toxicity
Evaluate renal function regularly, assess need for prolonged therapy, and monitor symptoms consistent with vestibulocochlear toxicity.
Use of finger-prick sampling, instead of venous sampling, can be considered for therapeutic drug monitoring of tobramycin.
Hammet-Stabler C, Johns T. Laboratory Guidelines for Monitoring Antimicrobial Drugs. Clin Chem. 1980. 44:5:1129-1140.
Isaacs D, Elliott E, Gilbert R, Moyer V, Pichichero M. Aminoglycosides: Dosing and Monitoring Blood Levels. Evidence-based Pediatric Infectious Diseases, Appendix 2. 2008. 301-305.
Tobramycin, random, serum. Mayo Clinic, Mayo Medical Laboratories. [Full Text].
Greco F. Therapeutic Drug Levels. Medline Encyclopedia. [Full Text].
Prescott WA Jr, Nagel JL. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis. Pharmacotherapy. 2010 Jan. 30(1):95-108. [Medline].
Coulthard KP, Peckham DG, Conway SP, Smith CA, Bell J, Turnidge J. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis–caution with trough concentrations. J Cyst Fibros. 2007 Apr. 6(2):125-30. [Medline].
Nicolau DP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995. 39(3):650-5.
Isaacs D, Elliott E, Gilbert R, Moyer V, Pichichero M. Aminoglycosides: Dosing and Monitoring Blood Levels. Evidence-based Pediatric Infectious Diseases. 2007. 301-305.
Edson RS, Terrell CL. Symposium on Antimicrobial Agents – Part VIII: The Aminoglycosides. Mayo Clin Proc. 1999. 74:519-528.
Green TP, Mirkin BL, Peterson PK, Sinaiko AR, Ramsay NK, O’Dea RF. Tobramycin serum level monitoring in young patients with normal renal function. Clin Pharmacokinet. 1984 Sep-Oct. 9(5):457-68. [Medline].
Tod MM, Padoin C, Petitjean O. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?. Clin Pharmacokinet. 2001. 40(11):803-14. [Medline].
Jones A, Beisty J, McKenna D, Clough D, Webb K, Morris J. Monitoring of tobramycin levels in patients with cystic fibrosis by finger-prick sampling. Eur Respir J. 2012 Jun. 39(6):1537-8. [Medline].
Paterson DL, Robson JM, Wagener MM, Peters M. Monitoring of serum aminoglycoside levels with once-daily dosing. Pathology. 1998 Aug. 30(3):289-94. [Medline].
Nightingale C, Ambrose P, Drusano G, Murakawa T. Antimicrobial Pharmacodynamics in Theory and Clinical Practices. 2nd edition. pg 161.
Reimann IR, Meier-Hellmann A, Pfeifer R, Traut T, Schilling A, Stein G. [Serum level-adjusted dosage of once-daily aminoglycoside therapy in critical illness: results of a prospective study]. Anasthesiol Intensivmed Notfallmed Schmerzther. 1999 May. 34(5):288-95. [Medline].
Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit. 2008 Dec. 30(6):674-81. [Medline].
Lemuel R Non, MD Resident Physician, Department of Internal Medicine, Albert Einstein Medical Center
Lemuel R Non, MD is a member of the following medical societies: American College of Physicians
Disclosure: Nothing to disclose.
Aaron R Kosmin, MD, AAHIVS, FACP Clinical Assistant Professor of Medicine, Jefferson Medical College of Thomas Jefferson University; Attending Physician, Section of Infection Diseases, Department of Medicine, Albert Einstein Medical Center
Aaron R Kosmin, MD, AAHIVS, FACP is a member of the following medical societies: American College of Physicians, American Society for Microbiology, Infectious Diseases Society of America, International Society for Infectious Diseases, HIV Medicine Association
Disclosure: Nothing to disclose.
Eric B Staros, MD Associate Professor of Pathology, St Louis University School of Medicine; Director of Clinical Laboratories, Director of Cytopathology, Department of Pathology, St Louis University Hospital
Eric B Staros, MD is a member of the following medical societies: American Medical Association, American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology
Disclosure: Nothing to disclose.
Tobramycin Level
Research & References of Tobramycin Level |A&C Accounting And Tax Services
Source